Clinical severity of SARS-CoV-2 Omicron BA.4 and BA.5 lineages compared to BA.1 and Delta in South Africa. Wolter, N., Jassat, W., Walaza, S., Welch, R., Moultrie, H., Groome, M. J., Amoako, D. G., Everatt, J., Bhiman, J. N., Scheepers, C., Tebeila, N., Chiwandire, N., du Plessis, M., Govender, N., Ismail, A., Glass, A., Mlisana, K., Stevens, W., Treurnicht, F. K., Subramoney, K., Makatini, Z., Hsiao, N., Parboosing, R., Wadula, J., Hussey, H., Davies, M., Boulle, A., von Gottberg, A., & Cohen, C. Nature Communications, 13:5860, Nature Publishing Group, oct, 2022. Paper doi abstract bibtex Omicron lineages BA.4 and BA.5 drove a fifth wave of COVID-19 cases in South Africa. Here, we use the presence/absence of the S-gene target as a proxy for SARS-CoV-2 variant/lineage for infections diagnosed using the TaqPath PCR assay between 1 October 2021 and 26 April 2022. We link national COVID-19 individual-level data including case, laboratory test and hospitalisation data. We assess severity using multivariable logistic regression comparing the risk of hospitalisation and risk of severe disease, once hospitalised, for Delta, BA.1, BA.2 and BA.4/BA.5 infections. After controlling for factors associated with hospitalisation and severe outcome respectively, BA.4/BA.5-infected individuals had a similar odds of hospitalisation (aOR 1.24, 95% CI 0.98–1.55) and severe outcome (aOR 0.72, 95% CI 0.41–1.26) compared to BA.1-infected individuals. Newly emerged Omicron lineages BA.4/BA.5 showed similar severity to the BA.1 lineage and continued to show reduced clinical severity compared to the Delta variant. South Africa experienced a resurgence in COVID-19 in 2022 driven by Omicron subvariants BA.4 and BA.5. Here, the authors investigate the severity of infections caused by these subvariants, and find no difference in the risk of severe outcomes when compared to Omicron BA.1, whilst all Omicron subvariants were less severe than Delta.
@article{Wolter2022d,
abstract = {Omicron lineages BA.4 and BA.5 drove a fifth wave of COVID-19 cases in South Africa. Here, we use the presence/absence of the S-gene target as a proxy for SARS-CoV-2 variant/lineage for infections diagnosed using the TaqPath PCR assay between 1 October 2021 and 26 April 2022. We link national COVID-19 individual-level data including case, laboratory test and hospitalisation data. We assess severity using multivariable logistic regression comparing the risk of hospitalisation and risk of severe disease, once hospitalised, for Delta, BA.1, BA.2 and BA.4/BA.5 infections. After controlling for factors associated with hospitalisation and severe outcome respectively, BA.4/BA.5-infected individuals had a similar odds of hospitalisation (aOR 1.24, 95{\%} CI 0.98–1.55) and severe outcome (aOR 0.72, 95{\%} CI 0.41–1.26) compared to BA.1-infected individuals. Newly emerged Omicron lineages BA.4/BA.5 showed similar severity to the BA.1 lineage and continued to show reduced clinical severity compared to the Delta variant. South Africa experienced a resurgence in COVID-19 in 2022 driven by Omicron subvariants BA.4 and BA.5. Here, the authors investigate the severity of infections caused by these subvariants, and find no difference in the risk of severe outcomes when compared to Omicron BA.1, whilst all Omicron subvariants were less severe than Delta.},
author = {Wolter, Nicole and Jassat, Waasila and Walaza, Sibongile and Welch, Richard and Moultrie, Harry and Groome, Michelle J. and Amoako, Daniel Gyamfi and Everatt, Josie and Bhiman, Jinal N. and Scheepers, Cathrine and Tebeila, Naume and Chiwandire, Nicola and du Plessis, Mignon and Govender, Nevashan and Ismail, Arshad and Glass, Allison and Mlisana, Koleka and Stevens, Wendy and Treurnicht, Florette K. and Subramoney, Kathleen and Makatini, Zinhle and Hsiao, Nei-yuan and Parboosing, Raveen and Wadula, Jeannette and Hussey, Hannah and Davies, Mary-Ann and Boulle, Andrew and von Gottberg, Anne and Cohen, Cheryl},
doi = {10.1038/s41467-022-33614-0},
file = {:C$\backslash$:/Users/01462563/AppData/Local/Mendeley Ltd./Mendeley Desktop/Downloaded/Wolter et al. - 2022 - Clinical severity of SARS-CoV-2 Omicron BA.4 and BA.5 lineages compared to BA.1 and Delta in South Africa.pdf:pdf},
issn = {2041-1723},
journal = {Nature Communications},
keywords = {2,CoV,Epidemiology,OA,Risk factors,SARS,Viral infection,fund{\_}ack,genomics{\_}fund{\_}ack,original},
mendeley-tags = {OA,fund{\_}ack,genomics{\_}fund{\_}ack,original},
month = {oct},
pages = {5860},
pmid = {36195617},
publisher = {Nature Publishing Group},
title = {{Clinical severity of SARS-CoV-2 Omicron BA.4 and BA.5 lineages compared to BA.1 and Delta in South Africa}},
url = {https://www.nature.com/articles/s41467-022-33614-0},
volume = {13},
year = {2022}
}
Downloads: 0
{"_id":"DRzDqgtgmrESfiLfs","bibbaseid":"wolter-jassat-walaza-welch-moultrie-groome-amoako-everatt-etal-clinicalseverityofsarscov2omicronba4andba5lineagescomparedtoba1anddeltainsouthafrica-2022","author_short":["Wolter, N.","Jassat, W.","Walaza, S.","Welch, R.","Moultrie, H.","Groome, M. J.","Amoako, D. G.","Everatt, J.","Bhiman, J. N.","Scheepers, C.","Tebeila, N.","Chiwandire, N.","du Plessis, M.","Govender, N.","Ismail, A.","Glass, A.","Mlisana, K.","Stevens, W.","Treurnicht, F. K.","Subramoney, K.","Makatini, Z.","Hsiao, N.","Parboosing, R.","Wadula, J.","Hussey, H.","Davies, M.","Boulle, A.","von Gottberg, A.","Cohen, C."],"bibdata":{"bibtype":"article","type":"article","abstract":"Omicron lineages BA.4 and BA.5 drove a fifth wave of COVID-19 cases in South Africa. Here, we use the presence/absence of the S-gene target as a proxy for SARS-CoV-2 variant/lineage for infections diagnosed using the TaqPath PCR assay between 1 October 2021 and 26 April 2022. We link national COVID-19 individual-level data including case, laboratory test and hospitalisation data. We assess severity using multivariable logistic regression comparing the risk of hospitalisation and risk of severe disease, once hospitalised, for Delta, BA.1, BA.2 and BA.4/BA.5 infections. After controlling for factors associated with hospitalisation and severe outcome respectively, BA.4/BA.5-infected individuals had a similar odds of hospitalisation (aOR 1.24, 95% CI 0.98–1.55) and severe outcome (aOR 0.72, 95% CI 0.41–1.26) compared to BA.1-infected individuals. Newly emerged Omicron lineages BA.4/BA.5 showed similar severity to the BA.1 lineage and continued to show reduced clinical severity compared to the Delta variant. South Africa experienced a resurgence in COVID-19 in 2022 driven by Omicron subvariants BA.4 and BA.5. Here, the authors investigate the severity of infections caused by these subvariants, and find no difference in the risk of severe outcomes when compared to Omicron BA.1, whilst all Omicron subvariants were less severe than Delta.","author":[{"propositions":[],"lastnames":["Wolter"],"firstnames":["Nicole"],"suffixes":[]},{"propositions":[],"lastnames":["Jassat"],"firstnames":["Waasila"],"suffixes":[]},{"propositions":[],"lastnames":["Walaza"],"firstnames":["Sibongile"],"suffixes":[]},{"propositions":[],"lastnames":["Welch"],"firstnames":["Richard"],"suffixes":[]},{"propositions":[],"lastnames":["Moultrie"],"firstnames":["Harry"],"suffixes":[]},{"propositions":[],"lastnames":["Groome"],"firstnames":["Michelle","J."],"suffixes":[]},{"propositions":[],"lastnames":["Amoako"],"firstnames":["Daniel","Gyamfi"],"suffixes":[]},{"propositions":[],"lastnames":["Everatt"],"firstnames":["Josie"],"suffixes":[]},{"propositions":[],"lastnames":["Bhiman"],"firstnames":["Jinal","N."],"suffixes":[]},{"propositions":[],"lastnames":["Scheepers"],"firstnames":["Cathrine"],"suffixes":[]},{"propositions":[],"lastnames":["Tebeila"],"firstnames":["Naume"],"suffixes":[]},{"propositions":[],"lastnames":["Chiwandire"],"firstnames":["Nicola"],"suffixes":[]},{"propositions":["du"],"lastnames":["Plessis"],"firstnames":["Mignon"],"suffixes":[]},{"propositions":[],"lastnames":["Govender"],"firstnames":["Nevashan"],"suffixes":[]},{"propositions":[],"lastnames":["Ismail"],"firstnames":["Arshad"],"suffixes":[]},{"propositions":[],"lastnames":["Glass"],"firstnames":["Allison"],"suffixes":[]},{"propositions":[],"lastnames":["Mlisana"],"firstnames":["Koleka"],"suffixes":[]},{"propositions":[],"lastnames":["Stevens"],"firstnames":["Wendy"],"suffixes":[]},{"propositions":[],"lastnames":["Treurnicht"],"firstnames":["Florette","K."],"suffixes":[]},{"propositions":[],"lastnames":["Subramoney"],"firstnames":["Kathleen"],"suffixes":[]},{"propositions":[],"lastnames":["Makatini"],"firstnames":["Zinhle"],"suffixes":[]},{"propositions":[],"lastnames":["Hsiao"],"firstnames":["Nei-yuan"],"suffixes":[]},{"propositions":[],"lastnames":["Parboosing"],"firstnames":["Raveen"],"suffixes":[]},{"propositions":[],"lastnames":["Wadula"],"firstnames":["Jeannette"],"suffixes":[]},{"propositions":[],"lastnames":["Hussey"],"firstnames":["Hannah"],"suffixes":[]},{"propositions":[],"lastnames":["Davies"],"firstnames":["Mary-Ann"],"suffixes":[]},{"propositions":[],"lastnames":["Boulle"],"firstnames":["Andrew"],"suffixes":[]},{"propositions":["von"],"lastnames":["Gottberg"],"firstnames":["Anne"],"suffixes":[]},{"propositions":[],"lastnames":["Cohen"],"firstnames":["Cheryl"],"suffixes":[]}],"doi":"10.1038/s41467-022-33614-0","file":":C$\\$:/Users/01462563/AppData/Local/Mendeley Ltd./Mendeley Desktop/Downloaded/Wolter et al. - 2022 - Clinical severity of SARS-CoV-2 Omicron BA.4 and BA.5 lineages compared to BA.1 and Delta in South Africa.pdf:pdf","issn":"2041-1723","journal":"Nature Communications","keywords":"2,CoV,Epidemiology,OA,Risk factors,SARS,Viral infection,fund_ack,genomics_fund_ack,original","mendeley-tags":"OA,fund_ack,genomics_fund_ack,original","month":"oct","pages":"5860","pmid":"36195617","publisher":"Nature Publishing Group","title":"Clinical severity of SARS-CoV-2 Omicron BA.4 and BA.5 lineages compared to BA.1 and Delta in South Africa","url":"https://www.nature.com/articles/s41467-022-33614-0","volume":"13","year":"2022","bibtex":"@article{Wolter2022d,\r\nabstract = {Omicron lineages BA.4 and BA.5 drove a fifth wave of COVID-19 cases in South Africa. Here, we use the presence/absence of the S-gene target as a proxy for SARS-CoV-2 variant/lineage for infections diagnosed using the TaqPath PCR assay between 1 October 2021 and 26 April 2022. We link national COVID-19 individual-level data including case, laboratory test and hospitalisation data. We assess severity using multivariable logistic regression comparing the risk of hospitalisation and risk of severe disease, once hospitalised, for Delta, BA.1, BA.2 and BA.4/BA.5 infections. After controlling for factors associated with hospitalisation and severe outcome respectively, BA.4/BA.5-infected individuals had a similar odds of hospitalisation (aOR 1.24, 95{\\%} CI 0.98–1.55) and severe outcome (aOR 0.72, 95{\\%} CI 0.41–1.26) compared to BA.1-infected individuals. Newly emerged Omicron lineages BA.4/BA.5 showed similar severity to the BA.1 lineage and continued to show reduced clinical severity compared to the Delta variant. South Africa experienced a resurgence in COVID-19 in 2022 driven by Omicron subvariants BA.4 and BA.5. Here, the authors investigate the severity of infections caused by these subvariants, and find no difference in the risk of severe outcomes when compared to Omicron BA.1, whilst all Omicron subvariants were less severe than Delta.},\r\nauthor = {Wolter, Nicole and Jassat, Waasila and Walaza, Sibongile and Welch, Richard and Moultrie, Harry and Groome, Michelle J. and Amoako, Daniel Gyamfi and Everatt, Josie and Bhiman, Jinal N. and Scheepers, Cathrine and Tebeila, Naume and Chiwandire, Nicola and du Plessis, Mignon and Govender, Nevashan and Ismail, Arshad and Glass, Allison and Mlisana, Koleka and Stevens, Wendy and Treurnicht, Florette K. and Subramoney, Kathleen and Makatini, Zinhle and Hsiao, Nei-yuan and Parboosing, Raveen and Wadula, Jeannette and Hussey, Hannah and Davies, Mary-Ann and Boulle, Andrew and von Gottberg, Anne and Cohen, Cheryl},\r\ndoi = {10.1038/s41467-022-33614-0},\r\nfile = {:C$\\backslash$:/Users/01462563/AppData/Local/Mendeley Ltd./Mendeley Desktop/Downloaded/Wolter et al. - 2022 - Clinical severity of SARS-CoV-2 Omicron BA.4 and BA.5 lineages compared to BA.1 and Delta in South Africa.pdf:pdf},\r\nissn = {2041-1723},\r\njournal = {Nature Communications},\r\nkeywords = {2,CoV,Epidemiology,OA,Risk factors,SARS,Viral infection,fund{\\_}ack,genomics{\\_}fund{\\_}ack,original},\r\nmendeley-tags = {OA,fund{\\_}ack,genomics{\\_}fund{\\_}ack,original},\r\nmonth = {oct},\r\npages = {5860},\r\npmid = {36195617},\r\npublisher = {Nature Publishing Group},\r\ntitle = {{Clinical severity of SARS-CoV-2 Omicron BA.4 and BA.5 lineages compared to BA.1 and Delta in South Africa}},\r\nurl = {https://www.nature.com/articles/s41467-022-33614-0},\r\nvolume = {13},\r\nyear = {2022}\r\n}\r\n","author_short":["Wolter, N.","Jassat, W.","Walaza, S.","Welch, R.","Moultrie, H.","Groome, M. J.","Amoako, D. G.","Everatt, J.","Bhiman, J. N.","Scheepers, C.","Tebeila, N.","Chiwandire, N.","du Plessis, M.","Govender, N.","Ismail, A.","Glass, A.","Mlisana, K.","Stevens, W.","Treurnicht, F. K.","Subramoney, K.","Makatini, Z.","Hsiao, N.","Parboosing, R.","Wadula, J.","Hussey, H.","Davies, M.","Boulle, A.","von Gottberg, A.","Cohen, C."],"key":"Wolter2022d","id":"Wolter2022d","bibbaseid":"wolter-jassat-walaza-welch-moultrie-groome-amoako-everatt-etal-clinicalseverityofsarscov2omicronba4andba5lineagescomparedtoba1anddeltainsouthafrica-2022","role":"author","urls":{"Paper":"https://www.nature.com/articles/s41467-022-33614-0"},"keyword":["2","CoV","Epidemiology","OA","Risk factors","SARS","Viral infection","fund_ack","genomics_fund_ack","original"],"metadata":{"authorlinks":{}}},"bibtype":"article","biburl":"https://drive.google.com/uc?export=download&id=1-YbiDDZeTcX0VKKZlqqSKulhgmeoOpLm","dataSources":["Krmt6gt9ktB2s6ARh","y6ojaHcuarkmc4yRQ"],"keywords":["2","cov","epidemiology","oa","risk factors","sars","viral infection","fund_ack","genomics_fund_ack","original"],"search_terms":["clinical","severity","sars","cov","omicron","lineages","compared","delta","south","africa","wolter","jassat","walaza","welch","moultrie","groome","amoako","everatt","bhiman","scheepers","tebeila","chiwandire","du plessis","govender","ismail","glass","mlisana","stevens","treurnicht","subramoney","makatini","hsiao","parboosing","wadula","hussey","davies","boulle","von gottberg","cohen"],"title":"Clinical severity of SARS-CoV-2 Omicron BA.4 and BA.5 lineages compared to BA.1 and Delta in South Africa","year":2022}